TherapeuticsMD (NYSE: TXMD) reported Q3 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $5.19 million versus the consensus estimate of $5.01 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.